Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Diltiazem

(Cardizem)

 

GCEMS Protocol:

 

  • Narrow Complex Tachycardia

 

Indications:

 

  • Rate control in refractory atrial fibrillation and SVT

 

Contraindications:

 

  • Concurrent or recent use of beta blockers

 

Side Effects:

 

  • Hypotension, heart block

 

Adult:

 

  • 20 mg IV/IO over 2 minutes if systolic BP > 90 mmHG
  • if uncontrolled after 15 minutes from initial dose, administer 25 mg IV/IO over 2 minutes if systolic BP > 90 mmHG